A newly developed drug can help combat the effects of postnatal depression.
NV-5138, a small molecule drug that mimics the action of ketamine, provides fast-acting antidepressant responses in rodent models of depression. The drug is currently undergoing Phase 1 testing in humans.
MDMA, a psychedelic drug, has successfully been used to reopen the 'critical period' of learning the reward values of social behaviors. Researchers report, in mature mice given MDMA, oxytocin triggers signaling in synapses that help encode social learning and memory, a process that does not usually occur in older animals. The findings could help in the development of treatments for PTSD and other disorders.
The mGlu2 receptor plays a critical role in the effectiveness of ketamine for treating depression.
A new study reports those who microdose psychedelics report improvements in attention and mental health. However, a number of people report an increase in neuroticism following six weeks of microdosing.
A new study reveals the combination of ketamine with naltrexone can help treat symptoms of both depression and addiction.
A new study reveals statins, biguanides and other drugs that help treat physical conditions may have significant benefits for the treatment of bipolar disorder and schizophrenia.
Ezogabine, an FDA approved anti-convulsant, appears to significantly reduce symptoms in those with major depressive disorder.
A new study reports microdosing psychedelics may enhance creative problem solving without risk of hallucinations, or trips, associated with taking high doses of the substances.